{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.30","upperLimit":"7.40","value":"5.50"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG001","lowerLimit":"9.50","upperLimit":"NA","value":"18.40"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG002","lowerLimit":"0.80","upperLimit":"NA","value":"1.05"},{"groupId":"OG003","lowerLimit":"1.90","upperLimit":"16.40","value":"5.70"},{"groupId":"OG004","lowerLimit":"2.10","upperLimit":"10.20","value":"7.80"},{"groupId":"OG005","lowerLimit":"2.50","upperLimit":"9.70","value":"4.80"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG006","lowerLimit":"0.30","upperLimit":"NA","value":"5.50"},{"groupId":"OG007","lowerLimit":"1.60","upperLimit":"33.00","value":"8.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"EFS is defined as the time in months between first dose of study drug and disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 1; FT-2102 (Single Agent)"},{"description":"Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 2; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG002","title":"Phase 2: Cohort 3; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG003","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG004","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"OG005","title":"Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG006","title":"Phase 2: Cohort 7; FT-2102 (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG007","title":"Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102","reportingStatus":"POSTED","timeFrame":"Phase 2: From first dose of study drug to disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy (up to 82 months)","title":"Phase 2: Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Months"}